Featured News Shoreline Biosciences to Present at 2024 Stifel Healthcare Conference November 15, 2024 Read More A highly efficient transgene knock-in technology in clinically relevant cell types June 20, 2023 Read More Press Releases Shoreline Biosciences to Present at 2024 Stifel Healthcare Conference November 15, 2024 READ MORE Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference August 3, 2023 READ MORE Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells March 16, 2023 READ MORE Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells March 16, 2023 READ MORE Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer February 21, 2023 READ MORE Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies January 19, 2023 READ MORE LOAD MORE Media A highly efficient transgene knock-in technology in clinically relevant cell types June 20, 2023 READ MORE A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs July 9, 2022 READ MORE BioWorld Insider Podcast: One-on-one with Medical Innovators February 7, 2022 READ MORE BioWorld Insider Podcast: One-on-one with Medical Innovators December 10, 2021 READ MORE Harnessing the body’s natural killers to target cancer December 5, 2021 READ MORE Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing November 8, 2021 READ MORE LOAD MORE
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference August 3, 2023 READ MORE
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells March 16, 2023 READ MORE
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells March 16, 2023 READ MORE
Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer February 21, 2023 READ MORE
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies January 19, 2023 READ MORE
A highly efficient transgene knock-in technology in clinically relevant cell types June 20, 2023 READ MORE
Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing November 8, 2021 READ MORE
